liposomal irinotecan II + oxaliplatin + fluorouracil + leucovorin

This investigational combination chemotherapy regimen consists of **irinotecan liposome injection II**, **oxaliplatin**, **5-fluorouracil (5-FU)**, and **leucovorin (LV)**. It is being evaluated by **Ruijin Hospital** as a second-line treatment for patients with pancreatic cancer, specifically those with liver-confined metastases who have failed first-line gemcitabine-based therapy (AG regimen). The regimen is uniquely administered via **hepatic arterial infusion chemotherapy (HAIC)**, which delivers high concentrations of the cytotoxic agents directly to the liver metastases through the hepatic artery, potentially enhancing local disease control while reducing systemic side effects. Irinotecan liposome II is a nanoparticle formulation of the topoisomerase I inhibitor irinotecan; oxaliplatin is a platinum-based DNA alkylating agent; 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase; and leucovorin is a folate analog used to stabilize the binding of 5-FU to its target enzyme, thereby increasing its efficacy.

Other names

HAIC-liposomal irinotecan II + oxaliplatin + 5-FU/LVirinotecan liposome injection II + oxaliplatin + fluorouracil + leucovorin